Long non-coding RNA HULC as a potential prognostic biomarker in human cancers: a meta-analysis

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Research

Background:

• Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in cancer development and progression.
• The lncRNA HULC (Highly Upregulated in Liver Cancer) has been observed to be dysregulated across multiple malignant tumors.

Purpose of the Study:

• To conduct a meta-analysis to evaluate the prognostic significance of HULC expression in human cancers.
• To determine the association between HULC expression levels and patient overall survival (OS).
• To assess the correlation between HULC expression and key pathological parameters such as lymph node metastasis (LNM), distant metastasis (DM), and tumor stage.

Main Methods:

• A systematic literature search was performed across major electronic databases (PubMed, Medline, OVID, Cochrane Library, Web of Science) up to August 14, 2016.
• Seven studies comprising 730 cancer patients were included in the meta-analysis.
• Hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using RevMan5.3 software to analyze the relationships between HULC expression and survival/pathological parameters.

Main Results:

• Higher HULC expression was significantly associated with improved overall survival (HR = 0.50, 95% CI: 0.35-0.70, P < 0.00001).
• Elevated HULC expression correlated with a lower likelihood of lymph node metastasis (OR = 0.20, 95% CI: 0.06-0.64).
• Higher HULC expression was also linked to reduced distant metastasis (OR = 0.27, 95% CI: 0.13-0.54) and less advanced tumor stage (OR = 0.39, 95% CI: 0.25-0.64).

Conclusions:

• The findings from this meta-analysis indicate that elevated HULC expression serves as a favorable prognostic biomarker in human cancers.
• HULC expression levels can potentially predict patient outcomes and disease progression, including metastasis and tumor staging.
• Further research into HULC's role could lead to novel diagnostic and therapeutic strategies in oncology.